Skip to content

Author

E. Stroes

We have 4 of 868 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Long-term efficacy and safety of olezarsen in patients with severe hypertriglyceridemia

Olezarsen, an antisense oligonucleotide that targets the mRNA for apolipoprotein C-III, reduced triglycerides (TGs) in patients with severe hypertriglyceridemia (sHTG, TG >500 mg/dL) by 50-72% at 6 months in two double-blinded placebo-controlled randomized clinical trials (RCTs, CORE-TIMI 72a, CORE2-TIMI 72b)....

R. Giugliano, N. Marston, B. Bergmark et al. · 0 citations
Review Open access Oct 2026

Design and baseline data of AZURE-HeFH, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with heterozygous familial hypercholesterolaemia

Patients with heterozygous familial hypercholesterolaemia (HeFH), if untreated or undertreated, are characterised by lifelong exposure to elevated low density lipoprotein cholesterol (LDLc) levels, associated with a markedly increased risk of atherosclerotic cardiovascular disease (ASCVD). Recent surveys, however...

E. Stroes, R. S. Rosenson, R. Santos et al. · 0 citations
Aug 2026

Efficacy and safety of olezarsen in patients with vs without baseline fibrate use.

Olezarsen reduced triglycerides across the hypertriglyceridemia spectrum, with greater effects in patients on background fibrates, particularly with diabetes, to support potential complementary mechanisms and further investigation of concomitant triglyceride-reducing therapy.

Annabel Z. Wang, V. Alexander, T. Prohaska et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.